TIEFENBACHER API + INGREDIENTS SECURES THE SUPPLY OF CONTROLLED SUBSTANCES FOR CUSTOMERS AND PATIENTS

We at TIEFENBACHER API + INGREDIENTS, a part of TIEFENBACHER GROUP, assure patients have a better access to controlled substance active pharmaceutical ingredients (API) to meet the needs of many indication fields including depression, post-traumatic stress disorder (PTSD), addiction, and pain management.

We are strongly convinced that distribution is creating a vast basket of added values to our customers and patients. One of the main values is to secure the steady supply of APIs; which has been proven during the current Covid-19 pandemic, the BREXIT, and exponentiates itself due to the requirement of “just in time deliveries”. Healing risks of out-of-stock scenarios and keeping a security buffer stock level is more important than ever. TIEFENBACHER API + INGREDIENTS has the necessary expertise, capabilities, and infrastructure to supply all APIs in line with increasingly stringent regulatory requirements to Europe.

Besides our strong pain treatment portfolio like Morphine, Buprenorphine, Oxycodone HCl and Hydromorphone HCl we also offering high potency products for intensive care like Sufentanil and Fentanyl. Furthermore, products like Methylphenidate and Dexamfetamine against the ADHS are completing our portfolio. We possess all the knowledge of regulations and can prove a strong track record of working with controlled substances, which is essential when ensuring the compliant handling of APIs and accelerating products from development to commercialization in the pharmaceutical industry.

Controlled substances combine with all regulations requirements are constantly available – and our whole portfolio includes more than 600+ APIs (Human + Veterinary) to secure the healthcare industry. For more information, please contact TIEFENBACHER API + INGREDIENTS:

Frank Tettinger f.tettinger@tifi-api.eu
Or please visit us on our TIEFENBACHER API + INGREDIENTS Website: www.tiefenbacher-api.com


TIEFENBACHER API + INGREDIENTS offers Pitavastatine Calcium for novel therapies

We at TIEFENBACHER API + INGREDIENTS help to bridge the gap between drug development and
market access by providing high purity of Pitavastatin Calcium (NK-104 hemicalcium, EU-DMF) to
assure patients have a better access to innovations and novel therapies.

Pitavastatine Calcium (CAS Number 147526-32-7), a relatively new developed cholesterol-lowering
agent (statin), is approved for the treatment of primary hyperlipidemia and mixed dyslipidemia, in
kids > 6 years old and adults. Major clinical benefits from statins appear due to the lowering LDL
levels, directly related to cardiovascular accidents.
Pitavastatine Calcium clinical trials have proved its efficacy in reducing LDL levels in dyslipidemia.
When compared to other statins for its effect to reduce LDL cholesterol, Pitavastatine is about 6-fold
more potent than Atorvastatin, 1.7-fold more potent than Rosuvastatin and 77-fold more potent
than Fluvastatin. Pitavastatine has also demonstrated less potential for the development of myalgia
allowing patients to attain their treatment goal.

Pitavastatine Calcium is immediately available in the highest quality reference for reliable results –
and our whole portfolio includes more than 600+ APIs (Human + Veterinary) to secure the
healthcare industry. For more information, please contact TIEFENBACHER API + INGREDIENTS:
Javier Ruiz j.ruiz@tifi-api.eu
Or please visit us on our TIEFENBACHER API + INGREDIENTS Website: www.tiefenbacher-api.com


TIEFENBACHER API + INGREDIENTS starts to offer the first API based on green chemistry

We at TIEFENBACHER API + INGREDIENTS are committed to drive green chemistry in the pharmaceutical raw material industry. Enviero Progesterone is an Active Pharmaceutical Ingredient (API) and the first molecule from TIEFENBACHER API + INGREDIENTS’ green-chemistry program by providing the latest in lower environmental impact products for patients around the world. Green chemistry is understood to have minimal impacts on the environment and human health, and also to be cost-effective.

Enviero Progesterone is produced on a synthesis that reduces waste, greenhouse gas emissions, and the use of hazardous solvents. As a result, out of this synthesis the carbon footprint of the Progesterone manufacturing process is reduced by more than 70 percent and eliminating the use of metal catalysts. This product is manufactured via a proprietary bio-catalytical process based on plant sterols.
According to the U.S. Environmental Protection Agency (EPA), Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.
TIEFENBACHER API + INGREDIENTS has been cooperating with the US-based manufacturer for
decades and is proud to start offering green chemistry API´s to our valuable customers in the pharmaceutical industry in Europe.

Enviero Progesterone is immediately available – and our whole portfolio includes more than 600+ API´s to secure the healthcare industry with high-quality solutions along the whole API value chain.
For more information, please contact TIEFENBACHER API + INGREDIENTS: Axel Hinsch a.hinsch@tifi-api.eu
Or please visit us on our TIEFENBACHER API + INGREDIENTS Website: www.tiefenbacher-api.com


TIEFENBACHER API + INGREDIENTS offer GMP certificated Natural Medicinal Cannabidiol (CBD) with highest purity profile in the market

We bring pharma-quality standards of cannabis API for the benefit of Patients in Europe. CBD, short for Cannabidiol, is a chemical compound from the Cannabis sativa plant. It has no psychotropic effects due to it is affinity for cannabinoid receptors CB1 and CB2 and which are part of the endocannabinoid system (ECS).

Pharmacological effect comprehends according to the medical literature positives effects in different autoimmune and neurogenerative pathologies such as multiple sclerosis (spasticity), arthritis, epilepsy (Lennox-Gastaut Syndrome and Dravet Syndrome), schizophrenia and other psychiatric disorders.

TIEFENBACHER API + INGREDIENTS can offer a CBD – white, crystalline substance isolated from industrial hemp in its purest form – manufactured in Europe with a purity > 99,5%, and an impurity profile of THC < 0,01%. By that minimizing side effects for patients.

Our partner for natural CBD is having a MHRA certified EU GMP certificate for both, human and veterinary use and complies with the requirements of the German Medicines Codex (DAC).

TIEFENBACHER API + INGREDIENTS covers the entire supply chain for medical cannabis with the highest pharmaceutical standards. For more information, please contact TIEFENBACHER API + INGREDIENTS: Patricia Wick p.wick@tifi-api.eu


TIEFENBACHER API + INGREDIENTS secures the supply of critical drug for COVID-19 Patients: Dexmedetomidine Hydrochloride

We ensure hospitals have access to the medicines needed for patient care, including Dexmedetomidine HCL. TIEFENBACHER API + INGREDIENTS delivers long-term solutions that help deliver top quality patient care throughout the pandemic and beyond.

Dexmedetomidine HCl, a novel sedative-analgesic agent and a front-line drug in our intensive care units becomes increasingly important for patients while it is on the FDA’s Drug Shortage List. The sudden rise is attributable to the global COVID-19 pandemic as Dexmedetomidine HCl  injectable is used to help put COVID-19 patients on to medical ventilators.

Its rising tendency is however expected to sustain beyond COVID-19 as tremendous research is being performed based on its advantageous sedating and analgesic properties compared to other alpha 2 agonists.

Dexmedetomidine HCl is currently being investigated and researched in various fields like e.g. Transdermal formulations, Intranasal formulations for treating pain, Oral thin film formulations and Dexmedetomidine slow release microneedle array.

In  veterinary practice  Dexmedetomidine HCl  is used for premedication and as an adjunct to general anesthesia.

Dexmedetomidine Hydrochloride is immediately  available – and our whole portfolio includes more than 600+ APIs to secure the healthcare industry. For more information, please contact TIEFENBACHER  API + INGREDIENTS:  Sandra Thiel s.thiel@tifi-api.eu


New TIEFENBACHER API website – part of the TIEFENBACHER GROUP Brand Relaunch

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API

“We are very thrilled to officially announce our new TIEFENBACHER API website, representing the raw material business of TIEFENBACHER GROUP, and aiming to expand our role as a high-quality distributor for active pharmaceutical ingredients. Our new website communicates a clear message of who we are, what we rise for and where our value lies when delivering on our best value seal: BETTER ACCESS, BETTER QUALITY, and BETTER SUPPLY.

The new API Website is an important milestone within the international brand relaunch of our whole company group (www.tiefenbachergroup.com) and represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Sören Schlosser and Oliver Schrader, Managing Directors TIEFENBACHER API


Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.